<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425789</url>
  </required_header>
  <id_info>
    <org_study_id>115/05</org_study_id>
    <nct_id>NCT00425789</nct_id>
  </id_info>
  <brief_title>Hyperbaric Therapy and Deep Chemical Peeling</brief_title>
  <official_title>Hyperbaric Therapy and Healing From Deep Chemical Peel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      To evaluate whether treatment with Hyperbaric oxygen can accelerate skin recovery after deep&#xD;
      peeling, and decrease frequency and severity of local side effects and complications.&#xD;
&#xD;
      20 post peel patients will recieve 5 daily hyperbaric treatments, starting from day 7 to&#xD;
      peel.Patient's followup will include self- filling questionnaire and photographs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 40 post-deep peel women (exoderm), older than 18 years old, treated by&#xD;
      the same dermatologist.&#xD;
&#xD;
      The treatment group will recieve 5 consecutive daily hyperbaric treatments, 1 hours long&#xD;
      each, at 2 ATF, starting from day 7 to peel. Prior to treatment, each patient will be signed&#xD;
      on informed consent and will have complete physical examination.&#xD;
&#xD;
      The control group will be matched by the following parameters: age, skin color and type, and&#xD;
      indication for peeling, and will be picked up by the dermatologist.&#xD;
&#xD;
      Patients will be excluded if they have known middle ear disease, chronic lung disease or&#xD;
      claustrophobia.&#xD;
&#xD;
      Follow -up:&#xD;
&#xD;
      The same dermatologist will follow-up, on regular dates: the follow-up examination will start&#xD;
      at day 1 to mask\occlusive dressing removal (equivalent to day 7 post-peel), and at days 7,&#xD;
      28, and after 3 months. All follow-up examinations will take place at noon (04-08 pm)&#xD;
      regularly.&#xD;
&#xD;
      Efficacy parameters:&#xD;
&#xD;
      All patients will be asked to fill up a daily questionnaire on the first week after peel, and&#xD;
      score the severity of pain, pruritus and tightness of facial skin (1 to 5). They will also&#xD;
      mention the daily analgesic usage.&#xD;
&#xD;
      Parameters that will be evaluated by the dermatologist during the study will be: tightness of&#xD;
      the skin, pain/burning, pruritus/stinging, swelling/edema, erythema, crusting, and scaling,&#xD;
      assessed on a 4-point severity scale (0- best, 3- worst).&#xD;
&#xD;
      Photographs:&#xD;
&#xD;
      Photographs of the patients in 5 angles views will be taken on the day of peel, day of mask&#xD;
      removal (7), day 28 and after 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">July 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chemical Peeling</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Treatment with Hyperbaric oxygen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study will include 40 post-deep peel women (exoderm), older than 18 years old,&#xD;
             treated by the same dermatologist (dr. Landau).&#xD;
&#xD;
          -  The treatment group will receive 5 consecutive daily hyperbaric treatments, 1 hours&#xD;
             long each, at 2 ATF, starting from day 7 to peel. Prior to treatment, each patient&#xD;
             will be signed on informed consent and will have complete physical examination.&#xD;
&#xD;
          -  The control group will be matched by the following parameters: age, skin color and&#xD;
             type, and indication for peeling, and will be picked up by the dermatologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if they have known middle ear disease, chronic lung disease&#xD;
             or claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tal Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shai Efrati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tal Friedman, MD</last_name>
    <phone>+972-574-225961</phone>
    <email>dr.tali@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shai Efrati, MD</last_name>
    <phone>+972-577-346364</phone>
    <email>efratishai@013.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research &amp; Development Unit, Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tal Friedman, MD</last_name>
      <phone>+972-574-225961</phone>
      <email>dr.tali@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shai Efrati, MD</last_name>
      <phone>+972-577-346364</phone>
      <email>efratishai@013.net</email>
    </contact_backup>
    <investigator>
      <last_name>Tal Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2007</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <keyword>Deep Chemical Peeling</keyword>
  <keyword>Hyperbaric Therapy</keyword>
  <keyword>post-deep peel</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

